Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: An ancillary study of the Novartis CICL670A0107 trial Academic Article uri icon

Overview

MeSH Major

  • Benzoates
  • Deferoxamine
  • Iron Chelating Agents
  • Oxidants
  • Triazoles
  • beta-Thalassemia

abstract

  • Iron chelation therapy with deferoxamine or with deferasirox was equally effective in decreasing iron burden and malondialdehyde. The possible differential effect of the two chelators on inflammation warrants further investigation.

publication date

  • June 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3324/haematol.11755

PubMed ID

  • 18469351

Additional Document Info

start page

  • 817

end page

  • 25

volume

  • 93

number

  • 6